idebenone has been researched along with Stroke in 3 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Excerpt | Relevance | Reference |
---|---|---|
"A 38-year-old patient with MELAS and SLEs was treated with oral L-arginine and idebenone for 27months." | 7.77 | Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient. ( Cho, TH; Derex, L; Kouamé-Assouan, AE; Lekoubou, A; Luauté, J; Nighoghossian, N, 2011) |
"Idebenone is a well-appreciated mitochondrial protectant while the mechanisms underlying the neuroprotection in cerebral ischemia and reperfusion (I/R) remain elusive." | 3.96 | Idebenone attenuates cerebral inflammatory injury in ischemia and reperfusion via dampening NLRP3 inflammasome activity. ( Gong, Z; He, L; Li, X; Pan, J; Peng, J; Peng, Y; Shen, Q; Wang, H, 2020) |
"An aim of the study was to assess the severity of asthenic syndrome, emotional disorders and quality of life indicators in post stroke patients treated with idebenone (noben)." | 3.79 | [Emotional disorders and quality of life in patients with post stroke asthenia]. ( Boĭko, AN; Ismailov, AM; Khozova, AA; Lebedeva, AV; Petrov, SV; Shchukin, IA; Shikhkerimov, RK; Soldatov, MA, 2013) |
"A 38-year-old patient with MELAS and SLEs was treated with oral L-arginine and idebenone for 27months." | 3.77 | Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient. ( Cho, TH; Derex, L; Kouamé-Assouan, AE; Lekoubou, A; Luauté, J; Nighoghossian, N, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Peng, J | 1 |
Wang, H | 1 |
Gong, Z | 1 |
Li, X | 1 |
He, L | 1 |
Shen, Q | 1 |
Pan, J | 1 |
Peng, Y | 1 |
Boĭko, AN | 1 |
Lebedeva, AV | 1 |
Shchukin, IA | 1 |
Soldatov, MA | 1 |
Petrov, SV | 1 |
Khozova, AA | 1 |
Ismailov, AM | 1 |
Shikhkerimov, RK | 1 |
Lekoubou, A | 1 |
Kouamé-Assouan, AE | 1 |
Cho, TH | 1 |
Luauté, J | 1 |
Nighoghossian, N | 1 |
Derex, L | 1 |
3 other studies available for idebenone and Stroke
Article | Year |
---|---|
Idebenone attenuates cerebral inflammatory injury in ischemia and reperfusion via dampening NLRP3 inflammasome activity.
Topics: Animals; Animals, Newborn; Brain Ischemia; Cells, Cultured; Encephalitis; Inflammasomes; Male; Mice; | 2020 |
[Emotional disorders and quality of life in patients with post stroke asthenia].
Topics: Affective Symptoms; Aged; Aged, 80 and over; Antioxidants; Female; Humans; Male; Middle Aged; Qualit | 2013 |
Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient.
Topics: Administration, Oral; Adult; Antioxidants; Arginine; Drug Combinations; Female; Humans; MELAS Syndro | 2011 |